COVID-19 Vaccines for Side Effects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial compares the side effects of two COVID-19 vaccines: the protein-based Novavax (Nuvaxovid, NVX-CoV2705) and the mRNA-based Pfizer. Researchers aim to determine which vaccine causes more or fewer post-vaccination symptoms, such as sore arms or tiredness. It suits adults who have received at least one COVID-19 vaccine and are eligible for a seasonal vaccine. As a Phase 4 trial, this research involves FDA-approved vaccines and helps to understand their benefits for more patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What is the safety track record for these treatments?
Research has shown that both the Novavax and Pfizer COVID-19 vaccines are generally safe. Studies have found that the Novavax vaccine is well-tolerated, with serious side effects occurring in less than 0.1% of cases. The FDA has approved it, confirming it meets safety standards for preventing COVID-19.
For the Pfizer-BioNTech vaccine, side effects are usually mild and resolve quickly. Common reactions include soreness at the injection site or a mild fever. Serious side effects, such as allergic reactions, are rare but possible. This vaccine also holds FDA approval, supporting its safety.
Both vaccines have been widely used and are considered effective in protecting against COVID-19.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about these treatments because Nuvaxovid (NVX-CoV2705) and the Pfizer-BioNTech COVID-19 vaccine offer unique approaches to managing side effects. Nuvaxovid is a protein-based vaccine, which means it uses harmless pieces of the virus to train the immune system, potentially leading to fewer side effects compared to traditional vaccines. On the other hand, the Pfizer-BioNTech vaccine utilizes mRNA technology, which instructs cells to produce a spike protein that prompts an immune response. This method has been groundbreaking in its ability to generate a robust immune response quickly. These innovative approaches provide promising alternatives to existing vaccines by offering different mechanisms that could minimize side effects for recipients.
What evidence suggests that this trial's vaccines could be effective for reducing COVID-19 vaccine side effects?
In this trial, participants will receive either the Novavax vaccine, Nuvaxovid, or the Pfizer-BioNTech COVID-19 vaccine. Studies have shown that the Novavax vaccine effectively prevents COVID-19, with an overall success rate of 90.4%. It uses a protein-based method, differing from the mRNA approach of some other vaccines. Research indicates it works well for individuals aged 12 and older. Meanwhile, the Pfizer-BioNTech COVID-19 vaccine has consistently provided strong protection against both mild and severe COVID-19 cases. This vaccine uses mRNA technology to help the body learn to fight the virus. Both vaccines effectively prevent COVID-19, offering good options for protection.13456
Are You a Good Fit for This Trial?
This trial is for individuals who are willing to report their reactions after receiving a COVID-19 vaccine. The specific eligibility criteria have not been provided, but typically participants would need to be in good health and without prior adverse reactions to vaccines.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Vaccination
Participants receive either the Novavax vaccine or an mRNA vaccine
Post-vaccination Monitoring
Participants report symptoms and side effects after receiving the vaccine
Follow-up
Participants are monitored for safety and effectiveness after vaccination
What Are the Treatments Tested in This Trial?
Interventions
- Nuvaxovid (NVX-CoV2705)
- Pfizer-BioNTech COVID-19 vaccine
Trial Overview
The study is comparing the reactogenicity, or side effects post-vaccination, between two COVID-19 vaccines: Pfizer-BioNTech's mRNA vaccine and Novavax's protein-based Nuvaxovid (NVX-CoV2373).
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
mRNA-based vaccine
Protein-based vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Marcel Curlin
Lead Sponsor
Citations
1.
ir.novavax.com
ir.novavax.com/press-releases/2025-08-27-Novavaxs-Nuvaxovid-TM-2025-2026-Formula-COVID-19-Vaccine-Approved-in-the-U-SNovavax's Nuvaxovid™ 2025-2026 Formula COVID-19 ...
Nuvaxovid is a vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 65 years of age and older, or ...
Novavax's COVID-19 Vaccine: Your Questions Answered
Trial results, published in The New England Journal of Medicine, showed it to have 90.4% overall efficacy.
Clinical Trial Results and Study Designs | NUVAXOVID™
Explore the efficacy of NUVAXOVID™ (COVID-19 Vaccine, Adjuvanted) for individuals 65+ and those 12-64 with an underlying condition that puts them at high ...
Nuvaxovid | European Medicines Agency (EMA)
Results from two main clinical trials found that Nuvaxovid was effective at preventing COVID-19 in people from 12 years of age when given as primary vaccination ...
Package Insert and Patient Package Insert - NUVAXOVID
Vaccine efficacy in participants without evidence of SARS-CoV-2 infection through 6 days after. 1118 the second dose is presented in Table 12. The efficacy of ...
NUVAXOVID™ Vaccine Tolerability Profile
Booster Dose: NUVAXOVID has a well established tolerability profile in patients aged 18+1,2. ≤0.1% of patients experienced higher severity (Grade 4) ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.